ARK Genomic Revolution ETF (BATS:ARKG) Reaches New 12-Month High – Still a Buy?

ARK Genomic Revolution ETF (BATS:ARKG)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $43.98 and last traded at $43.86, with a volume of 1805851 shares changing hands. The stock had previously closed at $42.91.

ARK Genomic Revolution ETF Stock Performance

The business’s 50-day simple moving average is $33.57 and its 200 day simple moving average is $30.76.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ARKG. NewEdge Advisors LLC boosted its position in ARK Genomic Revolution ETF by 49.4% during the 1st quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock valued at $112,000 after buying an additional 1,780 shares during the period. Creative Planning purchased a new position in shares of ARK Genomic Revolution ETF in the second quarter valued at about $255,000. Baird Financial Group Inc. raised its stake in shares of ARK Genomic Revolution ETF by 81.0% during the second quarter. Baird Financial Group Inc. now owns 71,977 shares of the company’s stock valued at $1,753,000 after acquiring an additional 32,221 shares during the last quarter. Strategic Wealth Investment Group LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the second quarter worth about $38,000. Finally, Group One Trading LLC bought a new stake in shares of ARK Genomic Revolution ETF in the second quarter worth about $2,274,000.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.